Drug intelligence / Profile preview

PPI-373

Development stage: Preclinical
Lead developer: Phoenix PharmaLabs
Modality: Small Molecules

Overview

PPI-373 is a novel opioid modulator that was part of a strategic collaboration between Aoxing Pharmaceutical and US-based Phoenix PharmaLabs. This partnership, established around 2010, aimed to co-develop and market Phoenix's opioid modulators, including PPI-373, for addiction treatments, leveraging Aoxing's narcotic infrastructure in China.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on PPI-373.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPI-373.

Explore the full profile